Bortezomib plus low dose cytarabine in Int-2 and high risk MDS. Interim results of a phase I/II trial by the GFM

被引：0
|
作者：
Natarajan, Shahti [1 ]
Fenaux, Pierre [1 ]
Vey, Norbert [1 ]
Guerci, A. [1 ]
Coulibaly, I. [1 ]
Charbonnier, A. [1 ]
Ravoet, C. [1 ]
Courby, S. [1 ]
Etienne, G. [1 ]
Chaury, M. P. [1 ]
Cheze, S. [1 ]
Stamatoullas, A. [1 ]
Legros, L. [1 ]
Berger, E. [1 ]
Lescoute, A. [1 ]
Vaultier, S. [1 ]
Dreyfus, F. [1 ]
机构：
[1] Grp Francophone Myelodysplasies, Paris, France
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1453
引用
收藏
页码：435A / 435A
页数：1
相关论文
共 50 条
  • [1] Lenalidomide (LEN) in INT 2 and high risk MDS with DEL 5q. Interim results of a phase II trial by the GFM
    Prebet, Burcheri T.
    Beyne-Rauzy, O.
    Mbida, R. M.
    Hoarau, N.
    Legros, L.
    Ravoet, C.
    Dreyfus, F.
    Stamatoullas, A.
    Chaury, M. P.
    Delaunay, J.
    Laurent, G.
    Vey, N.
    Ade, L.
    Gardin, C.
    Fenaux, Pierre
    BLOOD, 2007, 110 (11) : 251A - 252A
  • [2] Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
    Natarajan-Ame, Shanti
    Park, Sophie
    Ades, Lionel
    Vey, Norbert
    Guerci-Bresler, Agnes
    Cahn, Jean-Yves
    Etienne, Gabriel
    Bordessoule, Dominique
    Ravoet, Christophe
    Legros, Laurence
    Cheze, Stephane
    Stamatoullas, Aspasia
    Berger, Elisabeth
    Schmidt, Aline
    Charbonnier, Aude
    Chaury, Marie-Pierre
    Braun, Thorsten
    Fenaux, Pierre
    Dreyfus, Francois
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 232 - 237
  • [3] CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM
    Peterlin, Pierre
    Turlure, Pascal
    Chevallier, Patrice
    Gourin, Marie-Pierre
    Dumas, Pierre-Yves
    Thepot, Sylvain
    Berceanu, Anna
    Park, Sophie
    Hospital, Marie Anne
    Cluzeau, Thomas
    Diaz, Jose Miguel Torregrosa
    Devron, Louis
    Chevret, Sylvie
    Bene, Marie C.
    Le Bris, Yannick
    Sapena, Rosa
    Chermat, Fatiha
    Dimicoli-Salazar, Sophie
    Fenaux, Pierre
    BLOOD, 2021, 138
  • [4] Azacitidine (AZA) plus idarubicin (IDA) in untreated high-risk MDS - A GFM phase I/II study
    Ades, L.
    De Renzis, B.
    Jeddi, R.
    Delaunay, J.
    Braun, T.
    Hunault-Berger, M.
    Stamatoullas, A.
    Sanhes, L.
    Samey, B.
    Chermat, F.
    Meddeb, B.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2013, 37 : S13 - S13
  • [5] Effect of deferasirox plus erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial
    Gattermann, Norbert
    Coll, Rosa
    Jacobasch, Lutz
    Allameddine, Allameddine
    Azmon, Amin
    DeBonnett, Laurie
    Bruederle, Andreas
    Jin, Jie
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (02) : 208 - 215
  • [6] Results of a phase II trial of azacitidine (AZA) with or without epoetin beta (EPO) in lower-risk MDS.
    Gardin, Claude
    Thepot, Sylvain
    Beyne-Rauzy, Odile
    Prebet, Thomas
    Park, Sophie
    Stamatoulas, Aspasia
    Guerci-Bresler, Agnes
    Cheze, Stephane
    Tertian, Gerard
    Choufi, B.
    Legros, Laurence
    Bastie, Jean Noel
    Delaunay, Jacques
    Wattel, Eric
    Dreyfus, Francois
    Vey, Norbert
    Boehrer, Simone
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] AZACITIDINE (AZA) COMBINED WITH IDARUBICIN (IDA) IN HIGHER RISK MDS (HRMDS) - RESULTS OF A PHASE I/II STUDY BY THE GFM
    Sebert, M.
    Ades, L.
    Stamatoullas, A.
    Braun, T.
    Delaunay, J.
    de Renzis, B.
    Jeddi, R.
    Meddeb, B.
    Berger, M. Hunault
    Samey, B.
    Chermat, F.
    Chaffaut, C.
    Chevert, S.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S63 - S63
  • [8] A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study.
    Prebet, Thomas
    Braun, Thorsten
    Rauzy, Odile Beyne
    Dreyfus, Francois
    Stamatoullas, Aspasia
    Wattel, Eric
    Ame, Shanti
    Raffoux, Emmanuel
    Delaunay, Jacques
    Salanoubat, Celia
    Mathieu, Isabelle
    Chermat, Fatiha
    Ades, Lionel
    Fenaux, Pierre
    Vey, Norbert
    BLOOD, 2010, 116 (21) : 1632 - 1632
  • [9] Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial
    Tong, Hongyan
    Zhou, Xinping
    Mei, Chen
    Zhang, Jin
    Lu, Ying
    Lan, Jianping
    Lin, Shengyun
    Zhuang, Yuefeng
    Kuang, Yuemin
    Ren, Yanling
    Ma, Liya
    Wei, Juying
    Ye, Li
    Xu, Weilai
    Li, Kongfei
    Lu, Chenxi
    Jin, Jie
    BLOOD, 2019, 134
  • [10] Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)
    Braun, Thorsten
    Raffoux, Emmanuel
    Prebet, Thomas
    Brechignac, Sabine
    Stamatoullas, Aspasia
    Dreyfus, Francois
    Hebibi, Zehaira
    Ades, Lionel
    Vey, Norbert
    Dombret, Herve
    Fenaux, Pierre
    Cardin, Claude
    BLOOD, 2011, 118 (21) : 279 - 280
12345